Palmitoylethanolamide for Chronic Inflammatory Pain Conditions - Trial NCT06273462
Access comprehensive clinical trial information for NCT06273462 through Pure Global AI's free database. This Phase 2 trial is sponsored by Navy Medical Center San Diego and is currently Not yet recruiting. The study focuses on Chronic Pain. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Navy Medical Center San Diego
Timeline & Enrollment
Phase 2
Mar 01, 2024
May 30, 2025
Primary Outcome
Pain Level
Summary
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide
 (PEA) is effective in reducing the pain in patients with chronic inflammatory pain
 conditions. The main question the trial aims to answer is if PEA works better at treating a
 patients pain and improving their function better than a placebo.
 
 Participants will be divided into two equal groups and asked to take either PEA or a placebo
 for 8 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06273462
Non-Device Trial